Polaryx Therapeutics, Inc. (PLYX): Submission of Matters to a Vote of Security Holders

SciSparc (SPRC) shares rose ~140% after its TSX Venture subsidiary received conditional approval to buy ~54% of private Israeli CliniQuantum for 56.6M NeuroThera shares (~$9.46M). Co-Diagnostics (CODX) gained ~53% for a third day amid Ebola PCR assay progress. Akari (AKTX) jumped ~38% on ASCO abstract acceptance and new KRAS-mutant synergy data; Outlook (OTLK) rose ~26% ahead of a June FDA resubmission.

Polaryx Therapeutics said it completed a PIPE financing of 2,502,696 shares at an average ~$4 per share, with no SEC registration statement for resale. The company plans to use $10 million gross proceeds plus existing cash to start its Phase 2 SOTERIA basket trial for PLX-200 across four LSDs, extending runway to Q2 2027. Shares were up 8.76% to $2.73.

CoreWeave (CRWV) shares dropped nearly 5% to below $80 after announcing a $3 billion convertible debt offering and a potential $2.92 billion equity raise to fund infrastructure expansion. The company aims to use proceeds for growth and to offset shareholder dilution, but the financing plans highlight its capital-intensive expansion and dependence on external funding.

GE Aerospace's CFO addressed durability concerns about the GE9X engine, assuring no delay for Boeing's 777X. The company redesigned the component and began shipping updated engines. GE's stock is trading at $313.47, 15.6% above its GF Value™ of $271.20, indicating modest overvaluation. The company's GF Score™ is 76/100, with strong momentum but mixed insider and guru activity.

Credit Acceptance Corp. agreed to a $700M settlement, including $630M in debt relief, $60M in restitution, and $15.5M in penalties. The deal, led by New York AG Letitia James and 39 other states, covers 55,000 borrowers. The company must change its default handling and add-on product sales practices. The settlement resolves allegations of predatory lending and misrepresentation of loan terms.

JPMorgan Chase (JPM) plans to invest $750 billion by 2035 to boost U.S. housing supply, including financing 1 million affordable units and aiding 500,000 homebuyers. The bank reported record Q2 net income of $21.2 billion, supporting its expanded housing efforts. Potential benefits include increased mortgage revenue and customer relationships, but risks include credit exposure and market conditions.